Sökresultat
Nya data för Spinraza bekräftar bibehållen effekt och säkerhet över tid för ett brett spektrum av patienter med spinal muskel atrofi
…rity,” said Alfred Sandrock, Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen. “New data show that continuous treatment with SPINRAZA for up to six and a half years improved or stabilized motor function and disease activity in a broad spectrum of patients with SMA. These results are in stark contrast to the expected natural history of the disease. Further, in a progressive disease like SMA, stabilization is an importa…
Crenezumab stoppade eller bromsade inte kognitiv försämring hos patienter med en specifik gen som orsakar tidig Alzheimer
…t,” said Eric M. Reiman, M.D., Banner Alzheimer’s Institute executive director and one of the study leaders. “At the same time, we’re proud of the impact that this precedent-setting trial has had in shaping a new era in Alzheimer’s prevention research and we’re extremely grateful to our research participants and their families. This trial, the data, samples and findings that we’ll share with the research community, and the related work that we and…
Call to Action: Implementation of Innovative, Global Strategies for Alzheimer’s Accurate Diagnosis
…ews Neurology represents an important step forward, laying out performance standards to guide health systems as they select and adopt blood tests in the United States. 1 Bridge healthcare system gaps to drive towards accessible, early, and accurate diagnosis. The first-of-its-kind DAC-SP AccDx program recently launched with 8 sites from 5 countries, to adopt innovative blood biomarker tests in the diagnostic pathway. Partners are already working t…
Eli Lillys Kisunla™ godkänd av FDA för behandling av tidig symtomatisk Alzheimers sjukdom
…nal information. ”This approval marks another step forward in evolving the standard of care for people living with Alzheimer’s disease that will ultimately include an arsenal of novel treatments, providing much needed hope to the Alzheimer’s community. As a physician, I am encouraged by the potential to stop treatment, which could reduce out-of-pocket costs and infusion burden for eligible patients,” said Howard Fillit, M.D., Co-Founder and Chief…
Dosering av natalizumab var sjätte vecka istället för var fjärde för personer med skovvis förlöpande multipel skleros
…istration of natalizumab Q6W and exploring the long-term efficacy, safety, and tolerability of natalizumab Q6W. The full manuscript, “Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a controlled, open-label, phase 3b trial,” is available onlineand will appear in the July print issue of The Lancet Neurology. In March 2022, the TYSABRITM (nat…